Small molecule · Antagonist of cysteinyl leukotriene type-1 receptor (CYSLTR1) · developed by Organon
Montelukast is an orally active leukotriene receptor antagonist that binds with high affinity and selectivity to the cysteinyl leukotriene 1 (CysLT1) receptor, blocking the inflammatory actions of leukotriene D4. It is studied in allergic rhinitis, where cysteinyl leukotrienes released from the nasal mucosa contribute to symptoms.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Apr 30, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01673620 | Phase 3 | Allergic Rhinitis | Completed | OGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Allergic Rhinitis
Updated Nov 15, 2026. Something wrong or missing? Report it on the OGN page.
See OGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OGN catalysts and pipeline →